Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Provided By GlobeNewswire
Last update: Nov 7, 2024
- Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signals -
Read more at globenewswire.com1.21
-0.07 (-5.47%)
Find more stocks in the Stock Screener
HOWL Latest News and Analysis
11 days ago - ChartmillTop movers in Tuesday's after hours sessionAs the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
